EF
NewAmsterdam Pharma Company Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Obicetrapib (TA-8995) | Hypercholesterolemia / HeFH / ASCVD | Phase 3 |
| Obicetrapib + Ezetimibe FDC | Hypercholesterolemia | Phase 3 |
Leadership Team at NewAmsterdam Pharma Company
DM
Dr. Michael Davidson
Co-founding Chief Executive Officer
PD
Professor Dr. John J.P. Kastelein
Co-founder and Chief Scientific Officer
BJ
B.J. Jones
Chief Commercial Officer
CB
Christie Ballantyne, M.D.
Chief of Cardiology (Baylor), Scientific Advisor